Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EBITDA (2019 - 2025)

Cyclerion Therapeutics has reported EBITDA over the past 7 years, most recently at -$976000.0 for Q3 2025.

  • Quarterly results put EBITDA at -$976000.0 for Q3 2025, down 34.99% from a year ago — trailing twelve months through Sep 2025 was -$3.6 million (up 33.13% YoY), and the annual figure for FY2024 was -$3.6 million, up 71.99%.
  • EBITDA for Q3 2025 was -$976000.0 at Cyclerion Therapeutics, up from -$1.7 million in the prior quarter.
  • Over the last five years, EBITDA for CYCN hit a ceiling of $502000.0 in Q4 2024 and a floor of -$16.2 million in Q2 2021.
  • Median EBITDA over the past 5 years was -$4.5 million (2022), compared with a mean of -$6.5 million.
  • Biggest five-year swings in EBITDA: surged 127.97% in 2024 and later plummeted 34.99% in 2025.
  • Cyclerion Therapeutics' EBITDA stood at -$14.3 million in 2021, then surged by 68.93% to -$4.5 million in 2022, then surged by 59.71% to -$1.8 million in 2023, then surged by 127.97% to $502000.0 in 2024, then plummeted by 294.42% to -$976000.0 in 2025.
  • The last three reported values for EBITDA were -$976000.0 (Q3 2025), -$1.7 million (Q2 2025), and -$1.5 million (Q1 2025) per Business Quant data.